Abstract
Unreasonable drug use and high drug prices will not only increase the burden on patients, but also increase the pressure on the expenditure of medical insurance funds. In the context of China's liberalization of government pricing of medicines, clarifying the role of the market and the government on the formation of drug prices is conducive to playing the joint role of the market and the government, and the establishment of a drug price formation mechanism adapted to the development of the pharmaceutical market. Through an in-depth study of drug price formation mechanisms and price control measures in Denmark, this paper explores the synergism of the market mechanism and the government intervention in drug price formation, and puts forward some suggestions for realizing dynamic management of drug prices, improving laws and regulations for the pharmaceutical industry, implementing classified price management for drugs, and applying diversified policies.
Key words
drug prices /
price formation /
price regulation /
market mechanism /
government intervention
Cite this article
Download Citations
Synergies Between the Market Mechanism and Government Intervention in Drug Price Formation——Enlightenment from Denmark[J]. China Health Insurance. 2024, 0(5): 53-59 https://doi.org/10.19546/j.issn.1674-3830.2024.5.007
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] OECD Data.Pharmaceutical spending[EB/OL].[2023-12-02].https://data.oecd.org/healthres/pharmaceutical-spending.htm.
[2] Danish Health Authority.The Danish healthcare system[EB/OL].(2023-06-14)[2024-01-13].https://www.sst.dk/en/english/general-public/the-danish-healthcare-system.
[3] Laegemiddelstyrelsen.Tilskud og priser[EB/OL]//Lægemiddelstyrelsen.(2024-03-01)[2024-05-21].https://laegemiddelstyrelsen.dk/da/tilskud/.
[4] Laegemiddelstyrelsen.Omregning til forbrugerpris[EB/OL]//Lægemiddelstyrelsen.(2024-01-08)[2024-5-21].https://laegemiddelstyrelsen.dk/da/tilskud/priser/omregning-til-forbrugerpris/.
[5] Retsinformation.LBK nr 339 af 15/03/2023, Indenrigs- og Sundhedsministeriet[EB/OL]//Retsinformation.(2023-03-15)[2023-12-07].http://www.retsinformation.dk/eli/lta/2023/339.
[6] AMGROS.3-kvartal[EB/OL].[2023-12-11].https://AMGROS.dk/media/fzwa0hj4/3-kvartal.pdf.
[7] Indenrigs-og-Sundhedsministeriet.Nye aftaler sikrer loft over medicinpriserne[EB/OL].(2023-03-31)[2023-12-10].https://www.ism.dk/nyheder/2023/marts/nye-aftaler-sikrer-loft-over-medicinpriserne-.
[8] Anders Munk-Nielsen.Forsker: Der findes en bedre løsning end referencepriser[EB/OL]//Sundhed.(2019-01-29)[2023-12-11].https://www.altinget.dk/sundhed/artikel/postdoc-referencepriser-loeser-ikke-medicinprisernes-himmelflugt.
[9] Christian Jervelund, BRENØE S, Morten Esketveit Rasmussen.Effekten af parallelimporteret medicin[J].Foreningen for Parallelimportører af Medicin,2022.
[10] Christoffer Miguel Frendesen.Apotekerforening: Prisloft kan sætte en stopper for dansk life science[EB/OL]//Sundhed.(2018-12-13)[2023-12-06].https://www.altinget.dk/sundhed/artikel/apotekerforening-prisloft-kan-saette-en-stopper-for-dansk-life-science.
